Hudson Bay Capital Management LP Biomarin Pharmaceutical Inc Transaction History

Hudson Bay Capital Management LP

$21.9 Billion
Q3 2024

A detailed history of Hudson Bay Capital Management LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 441,200 shares of BMRN stock, worth $29.7 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

441,200

Previous 244,700 80.3%

Holding current value

$29.7 Million

Previous $20.1 Million 53.93%

% of portfolio

0.14%

Previous 0.11%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $13.6 Million - $18.4 Million	196,500 Added 80.3%	441,200 $31 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $10 Million - $12.4 Million	134,800 Added 122.66%	244,700 $20.1 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $2.96 Million - $3.49 Million	35,287 Added 47.29%	109,900 $9.6 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $4.29 Million - $5.55 Million	-56,297 Reduced 43.0%	74,613 $7.19 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $6.63 Million - $7.36 Million	77,910 Added 147.0%	130,910 $11.6 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $1.99 Million - $2.31 Million	23,000 Added 76.67%	53,000 $4.59 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $5.26 Million - $7.04 Million	-60,000 Reduced 66.67%	30,000 $2.92 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $1.21 Million - $1.63 Million	-15,000 Reduced 14.29%	90,000 $9.31 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $2.95 Million - $3.48 Million	-35,890 Reduced 25.47%	105,000 $8.9 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $6.68 Million - $8.11 Million	93,390 Added 196.61%	140,890 $11.7 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $1.3 Million - $1.62 Million	17,500 Added 58.33%	47,500 $3.66 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $5.02 Million - $6.4 Million	-70,000 Reduced 70.0%	30,000 $2.65 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $1.12 Million - $1.28 Million	15,000 Added 17.65%	100,000 $7.73 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $566,325 - $635,925	-7,500 Reduced 8.11%	85,000 $7.09 Million
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $186,825 - $226,725	-2,500 Reduced 2.63%	92,500 $6.99 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $3.14 Million - $3.91 Million	43,300 Added 83.75%	95,000 $8.33 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $1.67 Million - $3.05 Million	-23,300 Reduced 31.07%	51,700 $3.93 Million
Q2 2020 Aug 12, 2020	SELL	$79.55 - $124.22 $795,500 - $1.24 Million	-10,000 Reduced 11.76%	75,000 $9.25 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $3.57 Million - $4.84 Million	-50,000 Reduced 37.04%	85,000 $7.18 Million
Q4 2019 Feb 12, 2020	SELL	$64.27 - $86.37 $1.78 Million - $2.39 Million	-27,700 Reduced 17.03%	135,000 $11.4 Million
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $4.23 Million - $5.34 Million	62,700 Added 62.7%	162,700 $11 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $842,000 - $986,200	-10,000 Reduced 9.09%	100,000 $8.88 Million
Q4 2018 Feb 13, 2019	BUY	$80.14 - $106.07 $801,400 - $1.06 Million	10,000 Added 10.0%	110,000 $9.37 Million
Q2 2018 Aug 13, 2018	SELL	$76.01 - $99.03 $3.04 Million - $3.96 Million	-40,000 Reduced 28.57%	100,000 $9.42 Million
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $2.33 Million - $2.78 Million	30,000 Added 27.27%	140,000 $11.4 Million
Q4 2017 Feb 12, 2018	SELL	$80.76 - $95.13 $6.1 Million - $7.18 Million	-75,500 Reduced 40.7%	110,000 $9.81 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $15 Million - $17.6 Million	185,500	185,500 $17.3 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Biomarin Pharmaceutical Inc Transaction History